Skip to main content
SpringerLink
Log in

Short communication: bendamustine-related hemolytic anemia in chronic lymphocytic leukemia

  • Short Communication
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Immune hemolytic anemia (IHA) may complicate the course of chronic lymphocytic leukemia (CLL), especially in patients with advanced disease, and as a complication of treatment with chlorambucil or fludarabine. Bendamustine, a novel agent with both alkylating and purine-analog properties, was approved in the USA for use in CLL in 2008. Since then, clinical data on its adverse events are accumulating. IHA related to bendamustine was seldom described and is thus reported and reviewed.

Methods

We assessed five cases of CLL patients complicated by IHA, out of 31 treated with bendamustine for a relapse of their disease. Also reviewed are previous case reports in the literature.

Results and conclusions

Bendamustine-related IHA is more common than suspected (16 %). No such cases were found in non-CLL patients. Personal history of fludarabine-triggered AIHA may be a risk factor for this complication (recorded in 4/5 patients, 80 %). The mechanism is thought to be related to the loss of T cell regulatory control as described for other agents. Physicians using bendamustine for the treatment for CLL should be aware of this complication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bastion Y, Coiffier B, Dumontet C, Espinouse D, Bryon PA (1992) Severe autoimmune hemolytic anemia in two patients treated with fludarabine for chronic lymphocytic leukemia. Ann Oncol 3:171–172

    PubMed  CAS  Google Scholar 

  2. Bergmann MA, Goebeler ME, Herold M, Emmerich B, Wilhelm M, Ruelfs C, Boening L, Hallek MJ (2005) Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL study group. Haematologica 90:1357–1364

    PubMed  CAS  Google Scholar 

  3. Borthakur G, O’Brien S, Wierda WG, Thomas DA, Cortes JE, Giles FJ, Kantarjian HM, Lerner S, Keating MJ (2007) Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab–incidence and predictors. Br J Haematol 136:800–805

    Article  PubMed  CAS  Google Scholar 

  4. Cheson BD, Wendtner CM, Pieper A, Dreyling M, Friedberg J, Hoelzer D, Moreau P, Gribben J, Knop S, Montillo M, Rummel M (2010) Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 10:21–27

    Article  PubMed  Google Scholar 

  5. D’Arena G, Cascavilla N (2007) Chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Leuk Lymphoma 48:1072–1080

    Article  PubMed  Google Scholar 

  6. Dearden C (2008) Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2008:450–456

    Article  Google Scholar 

  7. Dearden C, Wade R, Else M, Richards S, Milligan D, Hamblin T, Catovsky D (2008) The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 111:1820–1826

    Article  PubMed  CAS  Google Scholar 

  8. Dennie TW, Kolesar JM (2009) Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Clin Ther 31(Pt 2):2290–2311

    Article  PubMed  CAS  Google Scholar 

  9. Fischer K, Cramer P, Busch R, Bottcher S, Bahlo J, Schubert J, Pfluger KH, Schott S, Goede V, Isfort S, von Tresckow J, Fink AM, Buhler A, Winkler D, Kreuzer KA, Staib P, Ritgen M, Kneba M, Dohner H, Eichhorst BF, Hallek M, Stilgenbauer S, Wendtner CM (2012) Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German chronic lymphocytic leukemia study group. J Clin Oncol 30:3209

    Article  PubMed  CAS  Google Scholar 

  10. Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, Bottcher S, Staib P, Kiehl M, Eckart MJ, Kranz G, Goede V, Elter T, Buhler A, Winkler D, Kneba M, Dohner H, Eichhorst BF, Hallek M, Wendtner CM (2011) Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German chronic lymphocytic leukemia study group. J Clin Oncol 29:3559–3566

    Article  PubMed  CAS  Google Scholar 

  11. Gandhi V, Burger JA (2009) Bendamustine in B-Cell malignancies: the new 46-year-old kid on the block. Clin Cancer Res 15:7456–7461

    Article  PubMed  CAS  Google Scholar 

  12. Ghia P, Scielzo C, Frenquelli M, Muzio M, Caligaris-Cappio F (2007) From normal to clonal B cells: chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity. Autoimmun Rev 7:127–131

    Article  PubMed  CAS  Google Scholar 

  13. Glance LE, Cumpston A, Kanate A, Remick SC (2009) Bendamustine-associated hemolytic anemia. Ann Pharmacother 43:1903–1906

    Article  PubMed  Google Scholar 

  14. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446–5456

    Article  PubMed  CAS  Google Scholar 

  15. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grunhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jager U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Buhler A, Winkler D, Zenz T, Bottcher S, Ritgen M, Mendila M, Kneba M, Dohner H, Stilgenbauer S (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376:1164–1174

    Article  PubMed  CAS  Google Scholar 

  16. Hodgson K, Ferrer G, Pereira A, Moreno C, Montserrat E (2011) Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment. Br J Haematol 154:14–22

    Article  PubMed  Google Scholar 

  17. Iannitto E, Morabito F, Mancuso S, Gentile M, Montanini A, Augello A, Bongarzoni V, D’Arco A, Di Renzo N, Fazzi R, Franco G, Marasca R, Mule A, Musso M, Musto P, Pennese E, Piccin A, Rota-Scalabrini D, Visani G, Rigacci L (2011) Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study. Br J Haematol 153:351–357

    Article  PubMed  CAS  Google Scholar 

  18. Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD (2010) Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 116:106–114

    PubMed  CAS  Google Scholar 

  19. Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Tremmel L, Merkle K, Montillo M (2009) Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27:4378–4384

    Article  PubMed  CAS  Google Scholar 

  20. Lewis FB, Schwartz RS, Dameshek W (1966) X-radiation and alkylating agents as possible “trigger” mechanisms in the autoimmune complications of malignant lymphoproliferative disease. Clin Exp Immunol 1:3–11

    PubMed  CAS  Google Scholar 

  21. Lissitchkov T, Arnaudov G, Peytchev D, Merkle K (2006) Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 132:99–104

    Article  PubMed  CAS  Google Scholar 

  22. Myint H, Copplestone JA, Orchard J, Craig V, Curtis D, Prentice AG, Hamon MD, Oscier DG, Hamblin TJ (1995) Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 91:341–344

    Article  PubMed  CAS  Google Scholar 

  23. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750–1757

    Article  PubMed  CAS  Google Scholar 

  24. Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, Schwartzberg LS, Lemieux B, Cheson BD (2008) Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol 26:4473–4479

    Article  PubMed  CAS  Google Scholar 

  25. Sanchez-Gonzalez B, Penalver FJ, Medina A, Guillen H, Calleja M, Gironella M, Arranz R, Sebastian E, De Ona R, Canovas A, de la Fuente I, Grande C, Sancho JM, Perez R, Domingo E, Lopez-Lorenzo JL, Prieto E, Panizo C, Gorosquieta A, Perez I, Cervera JM, Marin M, Mencha C, Ramila E, Salar A (2011) Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain. Leuk Res 36:709

    Article  PubMed  Google Scholar 

  26. Tosti S, Caruso R, D’Adamo F, Picardi A, Ali Ege M, Girelli G, Mauro FR, Maurillo L, Amadori S (1992) Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine-based treatment. Ann Hematol 65:238–239

    Article  PubMed  CAS  Google Scholar 

  27. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S (2010) From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 10:37–50

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Hadassah-Hebrew University Medical Center, POB 12000, 91120, Jerusalem, Israel

    Neta Goldschmidt, Alexander Gural, Dina Ben-Yehuda & Moshe E. Gatt

Authors
  1. Neta Goldschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander Gural
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dina Ben-Yehuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Moshe E. Gatt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Moshe E. Gatt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goldschmidt, N., Gural, A., Ben-Yehuda, D. et al. Short communication: bendamustine-related hemolytic anemia in chronic lymphocytic leukemia. Cancer Chemother Pharmacol 72, 709–713 (2013). https://doi.org/10.1007/s00280-013-2243-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-013-2243-5

Keywords

Search

Navigation